Investigators report promising results from Phase II trial of targeted therapy for rare bi

Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer. Results of the ongoing eNRGy trial, a single-arm, multicenter, global Phase II clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy—including a near doubling of progression-free survival compared with expectations with standard of care—in previously treated patients with advanced NRG1-positive cholangiocarcinoma.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: Results of the ongoing eNRGy trial, a single-arm, multicenter, global Phase II clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy—including a near doubling of progression-free survival compared with expectations with standard of care—in previously treated patients with advanced NRG1-positive cholangiocarcinoma.

• Ponto de atenção: investigators.
• Ponto de atenção: report.
• Ponto de atenção: promising.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.